The UK-based company, founded in 2008, has a team of internationally recognised scientists who carry out scientific due diligence prior to investment. GBP typically invests between £50-200k in companies operating in the life sciences, biologic drug discovery, antibody, alternative scaffold, protein, peptide, regenerative medicine, immuno-diagnostics device, and immuno-platform technology sectors. The company has made ten investments in Scotland and one in a Malaysian company looking to relocate part of its business to Scotland.